Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation

Current Opinion in Hematology

Volumn 18, Issue 6, 2011, Pages 388-394

  Oran, Betul ^a,b   De Lima, Marcos ^c  

^a Blood and Marrow Transplantation Program   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

acute myeloid leukemia; allogeneic stem cell transplantation; prevention; relapse

Indexed keywords

AZACITIDINE; CD135 ANTIGEN; HLA A ANTIGEN; MOLECULAR MARKER; PEPTIDE VACCINE; SORAFENIB; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHROMOSOME BANDING PATTERN; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG MECHANISM; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 80054759339     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32834b6158     Document Type: Review

References (63)

1. Meijer E, Cornelissen JJ. Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: Weighing prognostic markers predicting relapse and risk factors for nonrelapse mortality. Semin Oncol 2008; 35:449-457.
2. Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: A review. Blood 1994; 84:3603-3612. (Pubitemid 24362455)
3. Mielcarek M, Storer BE, Flowers ME, et al. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13:1160-1168. (Pubitemid 47413010)
4. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: A retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25:4938-4945. (Pubitemid 350225492)
5. Oran B, Giralt S, Couriel D, et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007; 21:2540-2544. (Pubitemid 350148900)
6. Porter DL, Collins RH Jr., Hardy C, et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95:1214-1221. (Pubitemid 30099829)
7. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21:4642-4649. (Pubitemid 46594039)
8. Candoni A, Tiribelli M, Toffoletti E, et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 2009; 82:61-68.
9. Bacher U, Badbaran A, Fehse B, et al. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol 2009; 37:135-142.
10. Hokland P, Ommen HB. Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood 2011; 117:2577-2584.
11. Chou WC, Tang JL, Wu SJ, et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 2007; 21:998-1004.
12. Cloos J, Goemans BF, Hess CJ, et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 2006; 20:1217-1220. (Pubitemid 43905824)
13. van der Velden VH, Hochhaus A, Cazzaniga G, et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: Principles, approaches, and laboratory aspects. Leukemia 2003; 17:1013-1034. (Pubitemid 36722231)
14. Voskova D, Schoch C, Schnittger S, et al. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry B Clin Cytom 2004; 62:25-38. (Pubitemid 39463698)
15. Inoue K, Ogawa H, Yamagami T, et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996; 88:2267-2278. (Pubitemid 26307931)
16. Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101:1698-1704. (Pubitemid 36237562)
17. Lange T, Hubmann M, Burkhardt R, et al. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 2011; 25:498-505. In this study, monitoring of WT1 expression and CD34(+) donor chimerism predicted relapse of AML and MDS after RIC-HCT.
18. Muller-Berat N, Lion T. Chimerism and transplant-related diagnostics. Leukemia 2006; 20: 1358-1360. (Pubitemid 44084047)
19. Huisman C, de Weger RA, de Vries L, et al. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant 2007; 39:285-291. (Pubitemid 46322635)
20. Wiedemann B, Klyuchnikov E, Kroger N, et al. Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia. Exp Hematol 2010; 38:1261-1271.
21. Pavletic SZ, Kumar S, Mohty M, et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant 2010; 16:871-890.
22. Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011; 29:1190-1197. In this study, pre-HCT MRD based on MFC was associated with increased risk of relapse and death after myeloablative HCT for AML in CR1, even after controlling for other risk factors.
23. Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication after transplant is associated with a decreased relapse risk: Evidence for a putative virus-versus-leukemia effect in AML patients. Blood 2011; 118:1402-1412.
24. Levine JE, Braun T, Penza SL, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20:405-412. (Pubitemid 34072522)
25. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038-1044.
26. Warren EH, Fujii N, Akatsuka Y, et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010; 115:3869-3878. In this study, adoptive transfer of donor T cells that recognize recipient mHAgs was used to prevent or to treat leukemic relapse after allo-HCT in seven patients. Adoptively transferred CTLs persisted in the blood up to 21 days after infusion, and five patients achieved complete but transient remissions after therapy.
27. Greiner J, Dohner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia: Definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 2006; 91:1653-1661. (Pubitemid 46039635)
28. Chen W, Norbury CC, Cho Y, et al. Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens. J Exp Med 2001; 193:1319-1326. (Pubitemid 32524782)
29. Oji Y, Oka Y, Nishida S, et al. WT1 peptide vaccine induces reduction in minimal residual disease in an imatinib-treated CML patient. Eur J Haematol 2010; 85:358-360.
30. Alatrash G, Molldrem JJ. Vaccines as consolidation therapy for myeloid leukemia. Expert Rev Hematol 2011; 4:37-50.
31. Sergeeva A, Alatrash G, He H, et al. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 2011; 117:4262-4272.
32. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111:236-242.
33. Mortimer J, Blinder MA, Schulman S, et al. Relapse of acute leukemia after marrow transplantation: Natural history and results of subsequent therapy. J Clin Oncol 1989; 7:50-57. (Pubitemid 19089081)
34. Pinto A, Attadia V, Fusco A, et al. 5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 1984; 64:922-929.
35. Sacco O, Lantero S, Scarso L, et al. Modulation of HLA-DR antigen and ICAM-1 molecule expression on airway epithelial cells by sodium nedocromil. Ann Allergy Asthma Immunol 1999; 83:49-54. (Pubitemid 30336811)
36. Goodyear O, Agathanggelou A, Novitzky-Basso I, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010; 116:1908-1918.
37. Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009; 115:1899-1905.
38. Lubbert M, Bertz H, Wasch R, et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 2010; 45:627-632.
39. Bolanos-Meade J, Smith BD, Gore SD, et al. 5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2011; 17:754-758.
40. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): An analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 2005; 106:3658-3665. (Pubitemid 41609208)
41. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1909-1918. (Pubitemid 351620111)
42. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: Sustained regression before and after allogeneic stem cell transplantation. Blood 2009; 113:6567-6571.
43. Sharma MR, Ravandi F, Bayraktar UD, et al. Treatment of FLT3-ITD positive acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant 2011 [Epub ahead of print].
44. Shaw BE, Mufti GJ, Mackinnon S, et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 2008; 42:783-789.
45. Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22:4872-4880. (Pubitemid 46638610)
46. Eapen M, Giralt SA, Horowitz MM, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004; 34:721-727. (Pubitemid 39406056)
47. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-2100. (Pubitemid 34229476)
48. Clausen J, Wolf D, Petzer AL, et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol 2007; 148:520-528. (Pubitemid 46701023)
49. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009; 113:726-732.
50. Baron F, Petersdorf EW, Gooley T, et al. What is the role for donor natural killer cells after nonmyeloablative conditioning? Biol Blood Marrow Transplant 2009; 15:580-588.
51. Meyer-Monard S, Passweg J, Siegler U, et al. Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation. Transfusion 2009; 49:362-371.
52. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-3057.
53. Berg M, Lundqvist A, McCoy P Jr., et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009; 11:341-355.
54. Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009; 69:4010-4017.
55. Platzbecker U, Wermke M, Radke J, et al. Minimal residual disease (MRD) based preemptive 5-azacytidine treatment can prevent or delay imminent relapse in patients with high-risk MDS or AML after allogeneic HSCT: Results of the 'RELAZA' trial. Blood 2010; 116:679.
56. de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: A dose and schedule finding study. Cancer 2010; 116:5420-5431. This phase I study showed that azacitidine at 32 mg/m2 given for 5 days is well tolerated and can be administered after allogeneic transplant for at least four cycles to heavily pretreated AML/MDS patients. The trial also suggested that this treatment may prolong event-free and overall survival, and that more cycles may be associated with greater benefit.
57. de Lima M, Bonamino M, Vasconcelos Z, et al. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: High remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant 2001; 27:73-78. (Pubitemid 32124409)
58. Yokoyama H, Lundqvist A, Su S, et al. Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation. Blood 2010; 116:2858-2859.
59. Sato T, Yang X, Knapper S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 2011; 117:3286-3293.
60. Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011; 117:3294-3301.
61. Andersson BS, Valdez BC, de Lima M, et al. Clofarabine +/- fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2011; 17:893-900.
62. Rosenthal J, Wong J, Stein A, et al. Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies. Blood 2011; 117:309-315. The regimen was well tolerated well with 1-year event-free survival of 65% suggesting that addition of total marrow and lymph node irradiation to RIC could be an alternative in patients who otherwise would not be eligible for RIC.
63. Pagel JM, Appelbaum FR, Eary JF, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006; 107:2184-2191. (Pubitemid 43289405)